Compounds > sdz imm 125

Page last updated: 2024-08-01 23:40:59

sdz imm 125

Description

SDZ IMM 125: structure given in first source; a hydroxyethyl derivative of serine(8)-cyclosporine; inhibits proliferation and functions of lymphocytes [MeSH]

Cross-References

ID Source	ID
PubMed CID	6436153
CHEMBL ID	217642
SCHEMBL ID	1229430
MeSH ID	M0204383

Synonyms (14)

Synonym
sdz imm 125
oxeclosporin
cyclo(((2s,3r,4r,6e)-3-hydroxy-4-methyl-2-(methylamino)-6-octenoyl)-l-2-aminobutyryl-n-methylglycyl-n-methyl-l-leucyl-l-valyl-n-methyl-l-leucyl-l-alanyl-o-(2-hydroxyethyl)-d-seryl-n-methyl-l-leucyl-n-methyl-l-leucyl-n-methyl-l-valyl)
oxeclosporin [inn]
CHEMBL217642
(3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-30-ethyl-12-(2-hydroxyethoxymethyl)-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,15,19,25,28-octamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritr
r7988d03jm ,
135548-15-1
unii-r7988d03jm
oxeclosporin [who-dd]
SCHEMBL1229430
sdz-imm 125
DTXSID10873121
Q27287882

Bioassays (3)

Assay ID	Title	Year	Journal	Article
AID102709	In vitro inhibition of interleukin-2 (IL-2) production induced by stimulating lymphocytes derived from mouse spleens with the mitogen canavalin A	1995	Journal of medicinal chemistry, May-26, Volume: 38, Issue:11 ISSN: 0022-2623	Preparation and in vitro activities of ethers of [D-serine]8-cyclosporin.
AID102701	In vitro efficacy to suppress lymphocyte proliferation as measured by the incorporation of a labeled precursor ([3H]- thymidine) into DNA in Mixed Lymphocyte reaction (MLR).	1995	Journal of medicinal chemistry, May-26, Volume: 38, Issue:11 ISSN: 0022-2623	Preparation and in vitro activities of ethers of [D-serine]8-cyclosporin.
AID102700	In vitro efficacy on humoral immune response by Mishell-Dutton assay (MD).	1995	Journal of medicinal chemistry, May-26, Volume: 38, Issue:11 ISSN: 0022-2623	Preparation and in vitro activities of ethers of [D-serine]8-cyclosporin.

Research

Studies (20)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	16 (80.00)	18.2507
2000's	4 (20.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (4.55%)	5.53%
Reviews	1 (4.55%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	20 (90.91%)	84.16%

Substance	Studies	Classes	Roles	First Year	Last Year	Average Age	Relationship Strength	Trials	pre-1990	1990's	2000's	2010's	post-2020
cyclosporine	1	homodetic cyclic peptide	anti-asthmatic drug; anticoronaviral agent; antifungal agent; antirheumatic drug; carcinogenic agent; dermatologic drug; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; geroprotector; immunosuppressive agent; metabolite	1995	1995	29.0	low	0	0	1	0	0	0

Substance	Studies	Classes	Roles	First Year	Last Year	Average Age	Relationship Strength	Trials	pre-1990	1990's	2000's	2010's	post-2020
verapamil	1	aromatic ether; nitrile; polyether; tertiary amino compound		2000	2000	24.0	low	0	0	1	0	0	0
lauric acid	1	medium-chain fatty acid; straight-chain saturated fatty acid	algal metabolite; antibacterial agent; plant metabolite	1996	1996	28.0	low	0	0	1	0	0	0
buthionine sulfoximine	1	diastereoisomeric mixture; homocysteines; non-proteinogenic alpha-amino acid; sulfoximide	EC 6.3.2.2 (glutamate--cysteine ligase) inhibitor; ferroptosis inducer	2002	2002	22.0	low	0	0	0	1	0	0
arachidonic acid	1	icosa-5,8,11,14-tetraenoic acid; long-chain fatty acid; omega-6 fatty acid	Daphnia galeata metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; human metabolite; mouse metabolite	1996	1996	28.0	low	0	0	1	0	0	0
endothelin-1	1			2000	2000	24.0	low	0	0	1	0	0	0
cyclosporine	9			1992	2002	28.4	high	0	0	8	1	0	0

Condition	Indicated	Studies	First Year	Last Year	Average Age	Relationship Strength	Trials	pre-1990	1990's	2000's	2010's	post-2020
Adjuvant Arthritis	0	1	1992	1992	32.0	low	0	0	1	0	0	0
Allergic Encephalomyelitis	0	1	1992	1992	32.0	low	0	0	1	0	0	0
Autoimmune Disease	0	1	1993	1993	31.0	low	0	0	1	0	0	0
Autoimmune Diseases	0	1	1993	1993	31.0	low	0	0	1	0	0	0
Body Weight	0	1	1992	1992	32.0	low	0	0	1	0	0	0
Cardiac Death	0	1	1992	1992	32.0	low	0	0	1	0	0	0
Delayed Hypersensitivity	0	1	1992	1992	32.0	low	0	0	1	0	0	0
Necrosis	0	1	2000	2000	24.0	low	0	0	1	0	0	0
Palmoplantaris Pustulosis	0	1	1995	1995	29.0	low	1	0	1	0	0	0
Psoriasis	0	1	1995	1995	29.0	low	1	0	1	0	0	0
Uveitis	0	1	1992	1992	32.0	low	0	0	1	0	0	0

Pharmacokinetics (1)

Article	Year
Physiologically based pharmacokinetic study on a cyclosporin derivative, SDZ IMM 125. Journal of pharmacokinetics and biopharmaceutics, , Volume: 22, Issue:5	1994

Bioavailability (3)

Article	Year
Absorption and disposition of SDZ IMM 125, a new cyclosporine derivative, in rats after single and repeated administration. Drug metabolism and disposition: the biological fate of chemicals, , Volume: 22, Issue:2
Uptake and metabolism of cyclosporin A and SDZ IMM 125 in the human in vitro skin2 dermal and barrier function models. Life sciences, , Volume: 57, Issue:3	1995
A new cyclosporin derivative, SDZ-IMM-125, prolongs renal allograft survival in dogs. Transplant immunology, , Volume: 3, Issue:2	1995

Dosage (2)

Article	Year
Absorption and disposition of SDZ IMM 125, a new cyclosporine derivative, in rats after single and repeated administration. Drug metabolism and disposition: the biological fate of chemicals, , Volume: 22, Issue:2
A new cyclosporin derivative, SDZ-IMM-125, prolongs renal allograft survival in dogs. Transplant immunology, , Volume: 3, Issue:2	1995